Why India and the UK have united to create Indo-UK Healthcare
The venture is backed by Healthcare UK, which is made up of the Department of Health (DH), UK Trade and Investment (UKTI) and NHS England. Meanwhile, the project is funded by £100 million of private investments.
The King’s College Hospital in New Chandigarh, Punjab will be the first of an expected 11 Indo-UK institutes of health throughout the country, and intends to bring India the best, most prestigious UK NHS hospitals and educational institutions to India.
Once completely implemented, the initiative will be a £1 billion investment into India’s healthcare system. It could potentially create up to 100,000 jobs, as the new medical and nursing colleges created will train 15,000 new MBBS doctors and 20,000 nurses.
RELATED TOPIC: Why the UK is the best European market for mHealth
Both nations agree they will benefit from the healthcare collaboration, as the UK has long been known as one of the most foreigner-friendly countries in the world due to its diverse mix of cultures. The Prime Ministers from each country recently came to terms on a Government-to-Government Implementation Taskforce to build the new institutes and create even more collaboration in other areas of healthcare.
An MoU has been signed between Indo-UK Helathcare and Mumbai-based Shapoorji Pallonji Group to construct the 11 health institutes. Funds for the project will be raised through a combination of debt and equity from a collection of banks such as the UK export credit agency, UK Export Finance, as well as leading private equity funds from investment banks including Elara Capital.
RELATED TOPIC: How NHS SBS is transforming health care procurement
“Our aim is to provide access to this unique service to as many of my fellow Indians as possible through the 11 Indo-UK Institutes of Health (IUIH) to deliver world class accountable healthcare which is ‘Affordable to All,’” said Dr. Ajay Rajan Gupta, who is the director and CEO of Indo-UK Healthcare. “Ango-Indian research collaborations in genetics and translational research would support delivery of better healthcare.”
Click here to read the latest edition of Healthcare Global magazine!
NHS trials test that predicts sepsis 3 days in advance
A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England.
Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year.
The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time.
From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.
Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction.
Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.
The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years.
If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.
Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”